Table 5. Characteristics of studies evaluating the impacts of cannabis use in individuals with Alzheimer’s disease or dementia.

Number of studies	Designs	Primary studies
		Cannabis use type	Funding
18	Systematic review: 9 [32, 36–38, 47, 49, 51, 53, 58]	Medical, overseen by physician: 9 [60, 72, 86–89, 148, 156, 158]	Non-industry: 5 [60, 72, 86–88]
	RCTs: 6 [60, 72, 86–89]		Mixed (industry and non-industry): 1 [89]
	Non-randomized trial: 2 [148, 156]		Not reported: 3 [148, 156, 158]
	Retrospective cohort: 1 [158]